Lv1
48 积分 2024-01-24 加入
Re: First-line Therapy for Advanced Non–Clear Cell Renal Cell Carcinoma. A Systematic Review and Meta-analysis
1个月前
已关闭
First-line Pembrolizumab Plus Lenvatinib for Advanced Non–clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial
1个月前
已完结
https://doi.org/10.1016/j.eururo.2025.05.019
1个月前
已关闭
Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline
1个月前
已完结
Preoperative mFOLFIRINOX versus PAXG for stage I–III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial
1个月前
已完结
Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial
1个月前
已完结
Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial
1个月前
已完结
Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES)
1个月前
已完结
Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial
1个月前
已完结
Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial
1个月前
已完结
皖公网安备34019202002308
